Compare iShares MSCI Indonesia ETF (EIDO) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Enveric Biosciences Inc — how do they compare? iShares MSCI Indonesia ETF trades at $11.87 (market cap $409.22M), while Enveric Biosciences Inc trades at $1.48 (market cap $6.80M). The key difference: iShares MSCI Indonesia ETF is far larger — about 60.2× Enveric Biosciences Inc's market cap, and iShares MSCI Indonesia ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 75 Days and Enveric Biosciences Inc for 14 Days on average.
| EIDO | ENVB | |
|---|---|---|
Market Cap | $409.22M | $6.80M |
Volume | 879,527 | 64,867 |
52-Week High | $19.22 | $10.80 |
52-Week Low | $10.80 | $1.27 |
Typical Hold Time | 75 Days | 14 Days |
Sector | — | Health |
Enterprise Value | — | -$1.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.82, down 0.34% with bearish technical signals from moving averages. The ETF faces weak price action despite attractive valuation metrics, with technical indicators showing mixed signals including a neutral RSI but bearish ADX readings. Trading volume declined 21% below average, indicating reduced investor interest.
The outlook remains cautious given persistent technical downtrend and Indonesia's limited benefit from commodity gains. While valuation appears attractive at 8.7x P/E, the 44% financials weighting and modest 5.9% long-term EPS growth constrain upside potential. Key risks include sector concentration and regional capital outflows from Asian equities.
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
